Anthony P Weiss1, A Eden Evins2, Lindsay E Jubelt3, Ruth S Barr1, Donald C Goff1, Tanya Logvinenko4. 1. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 2. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; MGH Center for Addiction Medicine, 60 Staniford Street, Boston, MA 02114, USA. 3. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 4. Biostatistics Division, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Abstract
RATIONALE: Nicotinic agonists may improve attention and memory in humans and may ameliorate some cognitive deficits associated with neuropsychiatric disorders such as schizophrenia. MATERIALS AND METHODS: We investigated the effects of a single dose of nicotine on episodic memory performance in 10 adults with schizophrenia and 12 healthy controls. Participants were nonsmokers in order to avoid confounding effects of nicotine withdrawal and reinstatement on memory. At each of two study visits, participants performed a test of episodic memory before and 4 h after application of a 14-mg transdermal nicotine (or identical placebo) patch in counterbalanced order. RESULTS: Compared with placebo, nicotine treatment was associated with more rapid and accurate recognition of novel items. There was a trend for a treatment by diagnosis interaction, such that the effect of nicotine to reduce false alarms was stronger in the schizophrenia than the control group. There was no effect of nicotine on accuracy or reaction time for identification of previously viewed items. CONCLUSIONS: These data suggest that nicotine improves novelty detection in non-smokers, an effect that may be more pronounced in non-smokers with schizophrenia. Because memory deficits are associated with functional impairment in schizophrenia and because impaired novelty detection has been linked to the positive symptoms of schizophrenia, study of the effects of chronic nicotinic agonist treatment on novelty detection may be warranted.
RCT Entities:
RATIONALE: Nicotinic agonists may improve attention and memory in humans and may ameliorate some cognitive deficits associated with neuropsychiatric disorders such as schizophrenia. MATERIALS AND METHODS: We investigated the effects of a single dose of nicotine on episodic memory performance in 10 adults with schizophrenia and 12 healthy controls. Participants were nonsmokers in order to avoid confounding effects of nicotine withdrawal and reinstatement on memory. At each of two study visits, participants performed a test of episodic memory before and 4 h after application of a 14-mg transdermal nicotine (or identical placebo) patch in counterbalanced order. RESULTS: Compared with placebo, nicotine treatment was associated with more rapid and accurate recognition of novel items. There was a trend for a treatment by diagnosis interaction, such that the effect of nicotine to reduce false alarms was stronger in the schizophrenia than the control group. There was no effect of nicotine on accuracy or reaction time for identification of previously viewed items. CONCLUSIONS: These data suggest that nicotine improves novelty detection in non-smokers, an effect that may be more pronounced in non-smokers with schizophrenia. Because memory deficits are associated with functional impairment in schizophrenia and because impaired novelty detection has been linked to the positive symptoms of schizophrenia, study of the effects of chronic nicotinic agonist treatment on novelty detection may be warranted.
Authors: E D Levin; C K Conners; D Silva; S C Hinton; W H Meck; J March; J E Rose Journal: Psychopharmacology (Berl) Date: 1998-11 Impact factor: 4.530
Authors: Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins Journal: Neuropsychopharmacology Date: 2007-04-18 Impact factor: 7.853
Authors: C Quisenaerts; M Morrens; W Hulstijn; E de Bruijn; M Timmers; J Streffer; J De la Asuncion; G Dumont; B Sabbe Journal: Psychopharmacology (Berl) Date: 2014-02 Impact factor: 4.530
Authors: Lauren V Moran; Luke E Stoeckel; Kristina Wang; Carolyn E Caine; Rosemond Villafuerte; Vanessa Calderon; Justin T Baker; Dost Ongur; Amy C Janes; A Eden Evins; Diego A Pizzagalli Journal: Psychopharmacology (Berl) Date: 2017-11-27 Impact factor: 4.530
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989
Authors: Sungwon Roh; Susanne S Hoeppner; David Schoenfeld; Catherine A Fullerton; Luke E Stoeckel; A Eden Evins Journal: Psychopharmacology (Berl) Date: 2013-10-11 Impact factor: 4.530
Authors: Matthew J Smith; Derin J Cobia; James L Reilly; Jodi M Gilman; Andrea G Roberts; Kathryn I Alpert; Lei Wang; Hans C Breiter; John G Csernansky Journal: Hippocampus Date: 2015-03-11 Impact factor: 3.899